Chronic Myeloid Leukemia (CML) is a type of cancer that affects the blood and bone marrow, characterized by the overproduction of myeloid cells. It is most commonly associated with a genetic mutation known as the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. CML progresses through three phases: chronic, accelerated, and blast crisis, with the chronic phase offering the best prognosis when diagnosed and treated early.

Several factors can increase the risk of developing CML, including advanced age, with most cases diagnosed in adults over 60 years old. Individuals with a history of genetic conditions, such as Down syndrome, or exposure to radiation or specific chemicals, such as benzene, may also face a higher risk. Additionally, there is a slight increase in occurrence among male populations compared to females.

Symptoms of CML can vary but often include fatigue, unexplained weight loss, night sweats, and a feeling of fullness due to spleen or liver enlargement. Patients may also experience frequent infections, easy bruising or bleeding, and bone pain as the disease progresses. In some cases, individuals may remain asymptomatic in the early phase of the disease, highlighting the importance of regular blood tests for early detection.

Chronic myeloid leukemia (CML) is primarily caused by a genetic mutation known as the Philadelphia chromosome, which results from a translocation between chromosomes 9 and 22. This abnormality leads to the production of a hybrid protein that promotes uncontrolled cell proliferation. While the exact triggers for this genetic change are not fully understood, exposure to high levels of radiation and certain chemical exposures, such as benzene, have been identified as potential risk factors.

CML is diagnosed through a combination of blood tests and bone marrow examination. A complete blood count (CBC) typically reveals elevated white blood cell counts, while cytogenetic testing, such as fluorescence in situ hybridization (FISH) or polymerase chain reaction (PCR), is used to detect the Philadelphia chromosome and confirm the diagnosis. Regular monitoring of molecular markers is also crucial for assessing response to treatment.

The management of chronic myeloid leukemia typically involves targeted therapies, particularly tyrosine kinase inhibitors (TKIs) like imatinib, which effectively inhibit the abnormal BCR-ABL protein associated with CML. In cases where patients develop resistance to TKIs or disease progression occurs, alternative medications or treatments such as second-generation TKIs, cytotoxic chemotherapy, or stem cell transplantation may be considered. A multidisciplinary approach, including ongoing monitoring and supportive care, is essential in optimizing patient outcomes.

Currently, there are no established methods for preventing CML, as the exact cause of the disease remains unclear. However, reducing exposure to known carcinogens, such as certain chemicals and radiation, may aid in lowering risk. Furthermore, maintaining a healthy lifestyle with a balanced diet, regular exercise, and routine medical check-ups can contribute to overall well-being and early detection of potential health issues.